Vocca raises $20M Series A for its AI medical receptionist

Vocca has raised a $20M Series A led by Norrsken VC, with Heal Capital, Speedinvest and Firstminute Capital participating, to scale an AI assistant that already answers more than 1 million patient phone calls a month across 1,500 medical practices in Europe and the US.

Nobody builds a startup dreaming of hold music – and yet the hold queue is exactly where patient access breaks first. The round, announced on 6 October 2026, lands barely fourteen months after the company was founded and takes its total funding to $25M (company announcement, 6 October 2026). Here is the round, the company behind it, and what the cheque says about where healthcare AI money is flowing this autumn.

Twenty million dollars for the front desk

The Series A is $20M, led by Norrsken VC, the Stockholm fund built by Klarna co-founder Niklas Adalberth. Heal Capital, Speedinvest and Firstminute Capital participate, alongside angel investors who include the founders of Alan and Datadog. Speedinvest and Firstminute had co-led Vocca’s $5.5M seed in September 2025, so the insiders doubled down rather than stepping aside (company announcement, 6 October 2026).

The money goes where the product already is: deeper scheduling infrastructure, channels beyond voice, more specialties and more complex scenarios, and a bigger US footprint. Vocca operates from New York, its headquarters, with a large part of the team in Paris.

“We’ve rarely seen customer love like this in healthcare,” said Alexander Danielsson, general partner at Norrsken VC, in the announcement.

From 2,000 to 15,000 practitioners in a year

Vocca was founded in July 2024 by Eliott Hoffenberg (CEO) and Hugo Danet (CTO). The product is an AI phone assistant for medical practices: it answers patient calls around the clock, books and reschedules appointments, explains how to prepare for an exam, and routes the cases it cannot close to a human. It plugs into the practice management software clinics already run, with specialty-specific scheduling logic for more than 20 specialties, from dentistry to radiology.

The growth numbers are the story. At the seed round a year ago, Vocca served 2,000 practitioners; today it serves 15,000 across 1,500 practices, handles more than 1 million inbound call conversations a month – a tenfold increase – and has grown revenue sevenfold, from an undisclosed base (all company figures, 6 October 2026). The assistant resolves about 70% of conversations end to end without a human, and above 85% at its most mature customers.

The European proof point is a Paris one: the Adolphe de Rothschild Foundation Hospital, the first French hospital to deploy an AI voice assistant, says Vocca resolves more than 75% of its calls fully autonomously, per deputy general director Charlotte Cardin-Taillia in the announcement. Hoffenberg’s own summary of the sales motion: “Practices don’t ask us about price. They ask how fast we can deploy and how we handle their edge cases.”

The team is about 40 people split between New York and Paris, and the company plans to hire roughly 40 more across both cities by the end of 2026.

A market compounding at 37.8%

So why does answering the phone deserve a $20M cheque? Because the segment is small and growing violently: the global market for AI voice agents in healthcare was worth $468M in 2024 and is projected to reach $3.18bn by 2030, a 37.8% CAGR over 2025-2030 (Grand View Research, May 2025, updated July 2026). The same report puts Germany on the largest European revenue share in 2024 and the UK as Europe’s fastest-growing market. For a Series A company, a growth rate like that means the land grab matters more than near-term margin – whoever owns the scheduling layer when the market has grown nearly sevenfold wins it.

For scale against our own funding data: in the same week, Paris-based WhiteLab Genomics raised $26M at Series B for AI in genomic medicine, and in late September Berlin’s Amara raised a €3.7M pre-seed for a voice-first eldercare companion. Vocca’s $20M sits at the top end of European healthcare AI Series A rounds this autumn.

French code, American invoices

The pattern worth watching is the company’s shape. Two French founders, a large engineering presence in Paris, headquarters in New York: we are seeing this silhouette again and again in applied AI, and healthcare sharpens it. The US, with its administrative sprawl, is where the revenue pool is deepest; Europe is where the product was proven, in a Paris hospital, in multiple languages, under GDPR. Unlike the previous generation, these teams are not relocating – they are distributing, keeping the talent where it is dense and planting the invoice address where the budgets are.

The good news is that the European side of that split is not the consolation prize. A phone assistant that survives French hospital bureaucracy and switches languages mid-call has a moat that a US-only competitor has to rebuild from scratch – and with European health rounds stacking up week after week, the capital to defend it is increasingly raised at home too.

A million calls a month, fourteen months in, from the least glamorous corner of healthtech. Watch the front desk – that is where healthcare AI is actually landing.